Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David W. Martin | M | 82 |
Pylum Biosciences, Inc.
 Pylum Biosciences, Inc. BiotechnologyHealth Technology Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA. | - |
| James L. Knighton | M | 70 |
Pylum Biosciences, Inc.
Pylum Biosciences, Inc. BiotechnologyHealth Technology Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA. | - |
| Kevin Cameron | M | 64 |
Pylum Biosciences, Inc.
Pylum Biosciences, Inc. BiotechnologyHealth Technology Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA. | - |
| Jeffery F. Miller | M | - |
Pylum Biosciences, Inc.
Pylum Biosciences, Inc. BiotechnologyHealth Technology Pylum Biosciences, Inc. develops and patents an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. Its platform modifies to generate new protein complexes to kill emerging strains as their genome sequences become available. The company was founded by James L. Knighton, Kevin Cameron, Jeffery F. Miller and David W. Martin and is headquartered in South San Francisco, CA. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Fran Klemens
- Personal Network
